| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ZG-10 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.003 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.088 | 0.003 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.003 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.003 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.003 |